Emcyt

Metastatic Hormone-Refractory Prostate Cancer
Treatment
2 FDA approvals
20 Active Studies for Emcyt

What is Emcyt

EstramustineThe Generic name of this drug
Treatment SummaryEstramustine is a medication that combines nitrogen mustard with the hormone estradiol. It is primarily used to treat prostate cancer and can also help protect against radiation.
Emcytis the brand name
image of different drug pills on a surface
Emcyt Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Emcyt
Estramustine
1992
1

Approved as Treatment by the FDA

Estramustine, otherwise known as Emcyt, is approved by the FDA for 2 uses such as refractory, metastatic hormone-refractory Prostate cancer and Metastatic Hormone-Refractory Prostate Cancer .
refractory, metastatic hormone-refractory Prostate cancer
Metastatic Hormone-Refractory Prostate Cancer

Effectiveness

How Emcyt Affects PatientsEstramustine is a medicine used to treat prostate cancer that has spread to other parts of the body or is progressing. It is a combination of estradiol and nitrogen mustard, which becomes activated in the body and causes damage to rapidly dividing cancer cells. This damage leads to cell death, which can shrink the size of the tumor.
How Emcyt works in the bodyEstramustine has two key components: an estrogen and a nitrogen mustard. The nitrogen mustard part is a powerful alkylating agent, meaning it can attach to and damage DNA strands. This causes cells to die, and also helps the drug bind to active estrogen receptors. As a result, estramustine can target cancer cells more effectively.

When to interrupt dosage

The proposed measure of Emcyt is subject to the diagnosed situation. The amount of dosage is contingent upon the administration technique (e.g. Oral or Capsule - Oral) detailed in the table below.
Condition
Dosage
Administration
Metastatic Hormone-Refractory Prostate Cancer
140.0 mg,
, Oral, Capsule, Capsule - Oral

Warnings

Emcyt Contraindications
Condition
Risk Level
Notes
Thromboembolism
Do Not Combine
Thrombophlebitis
Do Not Combine
There are 20 known major drug interactions with Emcyt.
Common Emcyt Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with Acteoside.
image of a doctor in a lab doing drug, clinical research

Emcyt Novel Uses: Which Conditions Have a Clinical Trial Featuring Emcyt?

88 active trials are underway to assess the potential of Emcyt to provide therapeutic benefits for patients with Prostate Cancer.
Condition
Clinical Trials
Trial Phases
Metastatic Hormone-Refractory Prostate Cancer
79 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Emcyt Reviews: What are patients saying about Emcyt?

4.7Patient Review
1/2/2008
Emcyt for Cancer of the Prostate Gland
I was amazed at how well this worked for my hormone independent prostate cancer. My PSA levels decreased from 10 to 4.8 in just 15 days of treatment with six capsules per day. In the following 30 days, it decreased again to 3.5.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about emcyt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Emcyt do?

"Emcyt is a prescription medication used to treat symptoms of prostate cancer. It may be used alone or with other medications. Emcyt belongs to a class of drugs called Antineoplastics, Hormones."

Answered by AI

How is Estramustine administered?

"To take estramustine, swallow it whole with water 3 to 4 times a day, at least one hour before or two hours after meals. You can take it at around the same times every day. Milk, milk products, and foods that contain calcium can make it harder for your body to absorb estramustine, so avoid them when taking this medication."

Answered by AI

Clinical Trials for Emcyt

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Therapy for Prostate Cancer

18+
Male
Jacksonville, FL
This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has increasing prostate-specific antigen after treatment (biochemically recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Typically drug-related cancer care is conducted at a medical center which causes patients to have to spend considerable time away from family, friends, and familiar surroundings. This separation may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. Therapy administered to a patient in the patients' residence in the comfort of familiar surrounding using Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) may help reduce psychological and financial distress, increase access to care and improve treatment compliance. Giving cancer therapy in the home compared in the clinic may be safe, tolerable and improve patient satisfaction with overall cancer care in Black men with locally advanced, biochemically recurrent or metastatic prostate cancer.
Phase 2
Recruiting
Mayo Clinic in FloridaRoxana S. Dronca, MD
Have you considered Emcyt clinical trials? We made a collection of clinical trials featuring Emcyt, we think they might fit your search criteria.Go to Trials
Image of Excel Diagnostics & Nuclear Oncology Center in Houston, United States.

Lutetium-177-PSMA-617 for Prostate Cancer

18+
Male
Houston, TX
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap. The study will enroll up to 30 men with metastatic castration-resistant prostate cancer, with an initial dosing approach that differs from the standard dose. The safety and tolerability of PLUVICTO will be evaluated in this study, with a focus on identifying the optimal dose for this population. This study addresses an important gap in understanding how Pluvicto performs in mCRPC patients with super scan findings.
Phase 2
Recruiting
Excel Diagnostics & Nuclear Oncology CenterEbrahim S. Delpassand, M.D. Chairman & Medical Director, MD., Nuclear Medicine
Image of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, United States.

Fasting for Prostate Cancer

18+
Male
Baltimore, MD
Activating the immune system to kill cancer cells is a promising therapeutic strategy for some patients with cancer. Unfortunately, current immune-targeting treatments do not work for patients with prostate cancer. In animal models of cancer, fasting can reprogram the body's metabolism and immune cell function to help immune cells kill cancer cells. The purpose of this study is to determine whether 7 days of water-only fasting or a very low-calorie diet is safe and feasible for patients with metastatic prostate cancer. This will help the investigators develop future studies to test whether incorporating periods of fasting or very low calorie diets into treatment plans for prostate cancer can improve outcomes from this disease.
Recruiting
Has No Placebo
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLaura Sena, MD, PhD
Have you considered Emcyt clinical trials? We made a collection of clinical trials featuring Emcyt, we think they might fit your search criteria.Go to Trials
Image of Dana Farber Cancer Institute in Boston, United States.

PSMA-PET/CT Scans for Prostate Cancer

18+
Male
Boston, MA
The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion of men with residual PSMA-avid disease on PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer? Do the findings on PSMA-PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer correlate with other markers of disease status, like PSA? Participants will: Receive standard of care treatment for metastatic hormone sensitive prostate cancer Undergo a PSMA-PET/CT scan before starting treatment Undergo a PSMA-PET/CT scan after 6 months of treatment Have a chart review every 3 months for 1 year after the 6 month PSMA-PET/CT scan
Phase 4
Waitlist Available
Dana Farber Cancer Institute (+1 Sites)Heather Jacene, MDBlue Earth Diagnostics
Have you considered Emcyt clinical trials? We made a collection of clinical trials featuring Emcyt, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security